These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 23148636)

  • 1. Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study.
    Nikitas N; Karadimou A; Tsitoura E; Soupos N; Tsiatas M; Karavasilis V; Pectasides D; Pavlidis N; Chrisofos M; Adamakis I; Murray S; Fountzilas G; Dimopoulos MA; Bamias A
    Pharmacogenomics; 2012 Nov; 13(14):1595-607. PubMed ID: 23148636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
    Park DJ; Zhang W; Stoehlmacher J; Tsao-Wei D; Groshen S; Gil J; Yun J; Sones E; Mallik N; Lenz HJ
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):162-6. PubMed ID: 16224397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
    Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer Group.
    Bamias A; Koutsoukos K; Gavalas N; Zakopoulou R; Tzannis K; Dedes N; Boulouta A; Fragkoulis C; Kostouros E; Dellis A; Mitsogiannis I; Adamakis I; Anastasiou I; Skolarikos A; Papatsoris A; Stravodimos K; Ferakis N; Pagoni S; Ntoumas K; Mitropoulos D; Deliveliotis C; Constantinides CA; Dimopoulos MA
    Curr Oncol; 2021 Nov; 28(6):4474-4484. PubMed ID: 34898581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.
    Kamikozuru H; Kuramochi H; Hayashi K; Nakajima G; Yamamoto M
    Int J Oncol; 2008 May; 32(5):1091-6. PubMed ID: 18425336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
    J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy.
    Yan L; Shu-Ying Y; Shan K; Yip BH; Rong-Miao Z; Na W; Hai-Yan S
    Pharmacogenomics; 2012 Mar; 13(4):419-27. PubMed ID: 22329723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
    Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.
    Su D; Ma S; Liu P; Jiang Z; Lv W; Zhang Y; Deng Q; Smith S; Yu H
    Lung Cancer; 2007 May; 56(2):281-8. PubMed ID: 17222938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.
    Chen C; Wang F; Wang Z; Li C; Luo H; Liang Y; An X; Shao J; Li Y
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):315-22. PubMed ID: 23712330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy.
    Palomba G; Atzori F; Budroni M; Ombra M; Cossu A; Sini M; Pusceddu V; Massidda B; Frau B; Notari F; Ionta M; Palmieri G
    J Transl Med; 2014 Sep; 12():272. PubMed ID: 25253066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
    Iranzo V; Sirera R; Bremnes RM; Blasco A; Jantus-Lewintre E; Tarón M; Berrocal A; Blasco S; Caballero C; Del Pozo N; Rosell R; Camps C
    Clin Lung Cancer; 2011 Jul; 12(4):224-30. PubMed ID: 21726821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.